7 research outputs found
Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report
No full textThe recommended therapy for chronic hepatitis C (CHC) infection is the combination of a Pegylated interferon and Ribavirin. Almost all such patients on combination therapy experience one or more adverse events during the course of treatment. Significant neurological side effects are rare. A few cases of Bell’s Palsy, chronic inflammatory demyelinating polyneuropathy and even one case of acute demyelinating polyneuropathy with atypical features for Guillain-Barre syndrome (GBS) associated with Interferon therapy have been reported but no report of GBS with typical features has been published. We present a case report of typical GBS associated with Peginterferon alfa-2a and Ribavirin used for treatment of CHC infection
S1261 Strong Predictors of Histologic Severity in Chronic Hepatitis B-Infected Patients Include Age, HBeAg Status and ALT Abnormality but Not the Viral Load
No full textS2079 The Majority of HCV-Infected Patients Presenting to a Large Hepatology Practice in An Urban Setting Cannot Be Treated with Pegylated Interferon and Ribavirin Due to Psychosocial Factors in Spite of Universal Health Insurance Access
No full text
